Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 171.83 billion. The enterprise value is 168.68 billion.

Market Cap	171.83B
Enterprise Value	168.68B

Important Dates

The last earnings date was Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	104.62M
Shares Outstanding	n/a
Shares Change (YoY)	+0.05%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	26.20M

Valuation Ratios

The trailing PE ratio is 48.25 and the forward PE ratio is 38.77.

PE Ratio	48.25
Forward PE	38.77
PS Ratio	14.46
PB Ratio	9.48
P/TBV Ratio	9.49
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	47.37
EV / Sales	14.20
EV / EBITDA	35.05
EV / EBIT	39.57
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	n/a
Interest Coverage	1,231.57

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	15.94%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	7.56M
Profits Per Employee	2.27M
Employee Count	1,377
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Concord Biotech has paid 1.18 billion in taxes.

Income Tax	1.18B
Effective Tax Rate	24.83%

Stock Price Statistics

The stock price has increased by +5.31% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+5.31%
50-Day Moving Average	1,839.65
200-Day Moving Average	1,859.61
Relative Strength Index (RSI)	34.48
Average Volume (20 Days)	6,020

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 11.88 billion and earned 3.56 billion in profits. Earnings per share was 34.03.

Revenue	11.88B
Gross Profit	7.71B
Operating Income	4.27B
Pretax Income	4.74B
Net Income	3.56B
EBITDA	4.82B
EBIT	4.27B
Earnings Per Share (EPS)	34.03

Full Income Statement

Balance Sheet

The company has 3.18 billion in cash and 29.69 million in debt, giving a net cash position of 3.15 billion.

Cash & Cash Equivalents	3.18B
Total Debt	29.69M
Net Cash	3.15B
Net Cash Per Share	n/a
Equity (Book Value)	18.13B
Book Value Per Share	173.28
Working Capital	n/a

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 64.92%, with operating and profit margins of 35.97% and 29.97%.

Gross Margin	64.92%
Operating Margin	35.97%
Pretax Margin	39.87%
Profit Margin	29.97%
EBITDA Margin	40.60%
EBIT Margin	35.97%
FCF Margin	n/a

Dividends & Yields

Concord Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-0.05%
Shareholder Yield	n/a
Earnings Yield	2.07%
FCF Yield	n/a

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1